Needham & Company LLC restated their buy rating on shares of Vaxcyte (NASDAQ:PCVX - Free Report) in a research report report published on Wednesday,Benzinga reports. They currently have a $140.00 price target on the stock.
PCVX has been the topic of several other reports. The Goldman Sachs Group started coverage on Vaxcyte in a research report on Friday, December 20th. They set a "buy" rating and a $135.00 target price on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $147.50.
Get Our Latest Analysis on Vaxcyte
Vaxcyte Trading Down 1.6 %
Shares of NASDAQ:PCVX traded down $1.20 on Wednesday, hitting $73.02. The company had a trading volume of 2,530,601 shares, compared to its average volume of 1,156,456. Vaxcyte has a 52-week low of $58.10 and a 52-week high of $121.06. The business has a 50 day moving average of $84.59 and a 200 day moving average of $94.71. The company has a market cap of $9.40 billion, a PE ratio of -15.87 and a beta of 0.98.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, equities analysts predict that Vaxcyte will post -4.21 EPS for the current year.
Insiders Place Their Bets
In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $92.49, for a total transaction of $739,920.00. Following the transaction, the chief operating officer now owns 205,695 shares of the company's stock, valued at $19,024,730.55. This trade represents a 3.74 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $92.45, for a total value of $1,386,750.00. Following the transaction, the chief executive officer now directly owns 450,301 shares in the company, valued at approximately $41,630,327.45. This represents a 3.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 76,616 shares of company stock valued at $6,766,481 in the last quarter. Insiders own 3.10% of the company's stock.
Institutional Trading of Vaxcyte
Several hedge funds have recently made changes to their positions in PCVX. Whipplewood Advisors LLC bought a new stake in shares of Vaxcyte in the 4th quarter worth approximately $28,000. Smartleaf Asset Management LLC increased its position in Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after acquiring an additional 260 shares during the period. National Bank of Canada FI acquired a new stake in Vaxcyte in the 4th quarter valued at approximately $41,000. Blue Trust Inc. increased its position in Vaxcyte by 33.5% in the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after acquiring an additional 93 shares during the period. Finally, Assetmark Inc. increased its position in Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock valued at $64,000 after acquiring an additional 775 shares during the period. Institutional investors own 96.78% of the company's stock.
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Featured Articles
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
